Regarding the therapeutic target for AD, treatment of mice with rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), was reported to prevent AD in mice with postnatal disruption of Tgfbr2 in SMCs, a model of Loeys-Dietz syndrome [17,20], and in another AD model that was induced by administration of β-aminopropionitrile (BAPN). This evidence concerns the gene MTOR and Alzheimer disease.